Selected for NEDO NEP Type B
We are pleased to announce that our company has been selected by the New Energy and Industrial Technology Development Organization (NEDO) to receive a grant of up to 30 million yen for the second “NEDO Entrepreneurs Program (NEP) Type B” for fiscal year 2021. We will use this funding to promote the social implementation of an early diagnosis method for pancreatic cancer using our single enzyme activity-based liquid biopsy.
“NEP (NEP) Type B” aims to promote and accelerate the commercialization of R&D startups by providing “entrepreneurial candidates” with opportunities to demonstrate the feasibility of their business plans utilizing specific technology seeds (Proof of Concept), funding for market research, training and individual mentoring for building business plans for commercialization, business plan presentations, and matching opportunities with investors and business companies.
We were selected from among 100 proposals, after an adoption screening by external experts and an internal review by NEDO.